Anavex Life Sciences Corp (AVXL)

[falconer66a]

Give us further guidance, please.

Preclinical studies in murines can be indicative of response in humans and encourage clinical trials, but they far from offers guarantees of success in humans as experienced biotech investors and biologist will know - well from experience .

Well, thanks. So helpful (maybe).

If you would, as an investor, please guide us specifically on how any of us should regard any or all of the published research data on blarcamesine. So far, all of it is "preclinical," in the sense that the drug has not yet gained regulatory approval for sale or therapeutic uses in any humans.

Should the existing published research data on blarcamesine, in both animals and humans, guide us in any way about taking an AVXL position? The published data look pretty good. Or, should we just discount those research data and wait around until the FDA approves the drug? Or, in the middle, take a small AVXL position, knowing full well that the drug's approval is yet contingent on the favorable completion of Phase 3 clinical studies?

That's what I've done. Over the years I've incrementally bought small numbers of AVXL; now own a few thousand shares. If my personal enthusiasm is not borne out in eventual FDA approval, my investment will be lost. On the other hand, if blarcamesine plays out as I believe the existing research data portend, I'll be worth several million US dollars. I'm comfortable with my position's risk/reward profile.

On the other hand, if I were to have in hand as cash the dollars I've used to acquire my AVXL position, and then take a new position after FDA approval, my eventual position value would be but fraction of what I presently envision. Buy early and cheap, and wait? Or, wait and buy late, with far lower eventual returns?

Differing biostock investment strategies. For me, the copious data from existing papers on blarcamesine research, which are virtually all positive, has directed my particular approach. We'll all see if this has been effective when the FDA makes a blarcamesine decision.